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حتديد الطفرات املسببة ملرض بوميب يف عينات أنسجة حمفوظة وتطوير الفحص 
اجلزيئي
علياء الأن�سارية، �سمرية الرواحية، طاهر باعمر، مرمي  النبهانية، اأناند داتي
امللخ�ص: الهدف: مر�ض بومبي )مر�ض تخزين الغليكوجني من النوع الثاين( هو مر�ض �سبغى ج�سدي متنحي لالختزان يف اجل�سيمات 
بهذا  الطفال امل�سابني  يفيد  ان  الأنزميية ميكن  للعالج بال�ستعا�سة  املبكر  ال�ستخدام  األفا غلوكوزيداز.  ينتج عن نق�ض حم�ض  احلالة 
الأن�سجة  من  النووي  احلم�ض  ا�ستخراج  مت  الدرا�سة،  هذه  يف  ال�رسيرية.  املظاهر  وتغايرية  املر�ض  ندرة  الت�سخي�ض  يعوق  ولكن  املر�ض 
الأر�سيفية )FFPET( لتحديد الطفرات امل�سببة ملر�ض بومبي يف عمان و عمل اختبار جزيئي. الطريقة: مت ت�سميم امل�رسعات الإنرتونية 
مل�ساعفة مقاطع ق�سرية )454-193 قاعدة مزدوجة( من املحورات 20-2( للبحث عن الطفرات با�ستخدام الت�سل�سل املبا�رس. النتائج: 
مت التعرف على طفرتني من الطفرات املت�سببة للمر�ض الوخيم يف عينتني. الأوىل برمز طفرة p.Arg854X( c.2560C<T(، والثانية 
التي مت  الطفرات  )PCR-RFLP( للك�سف عن  c.1327-2A<G. مت ت�سميم الختبار اجلزيئي  وجدت عند موقع املتقبل امل�سفر 
حتديدها. اخلال�صة: ميكن لهذه الختبارات ت�سهيل الت�سخي�ض قبل الولدة وامل�ساعدة يف حتديد الأفراد الذين يحملون الطفرات يف الأ�رس 
التي مت حتديد الطفرات فيها.
مفتاح كلمات: مرض بوميب؛ غلوكان 4،1 ألفا غلوكوزيداز؛ نسيج؛ الطفرات؛ طرق التنميط اجليين؛ عمان. 
abstract: Objectives: Pompe disease (glycogen storage disease type II) is a rare autosomal recessive lysosomal 
storage disease that is caused by acid alpha-glucosidase deficiency. Early enzyme replacement therapy can benefit 
infants with the disease but the diagnosis is complicated by the rarity of the disease and the heterogeneity of the 
clinical manifestations. In this study, DNA extracted from archival postmortem formalin-fixed paraffin-embedded 
tissues was used to identify Pompe disease mutations in Oman and develop a rapid molecular-based test. Methods: 
Intronic primers were designed to amplify short fragments (193–454 base pairs [bp]) from coding exons (2–20) and 
screen for mutations using direct sequencing (DS). Results: Two mutations known to cause severe disease were 
identified in two samples. One was a coding mutation, c.2560C>T (p.Arg854X), and the second was found at a splice 
acceptor site, c.1327-2A>G. Polymerase chain reaction- and restriction fragment length polymorphism-based tests 
were designed for the rapid genotyping of the identified mutations. Conclusion: These tests can facilitate prenatal 
diagnosis and help in identifying carriers in families with the identified mutations.
Keywords: Pompe Disease; Glucan 1,4-alpha-Glucosidase; Tissue; Mutations; Genotyping Techniques; Oman.
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Advances in Knowledge
- This study identified two genetic mutations causing Pompe disease in two Omani patients.
Application to Patient Care
- The molecular test designed in this study can facilitate prenatal diagnosis and the screening of at-risk infants.
Pompe disease is a rare autosomal recessive disease, classified as a lysosomal storage disorder. It is caused by an acid 
alpha-glucosidase (GAA EC. 3.2.1.20) deficiency, 
which results in the accumulation of glycogen 
within the lysosomes and the cytoplasm of the 
cardiac, skeletal and smooth muscle cells. The 
clinical spectrum of the disease varies in terms of 
the age of onset, the disease progression rate and 
the extent of organ involvement.1,2
Because of the continuous clinical spectrum of 
Pompe disease, Gungor and Reuser proposed three 
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subtypes: classic infantile, childhood and adult.3 
The first is characterised by an onset of symptoms 
within the first year of life, which is always 
associated with hypertrophic cardiomyopathy and a 
total lack of acid α-glucosidase activity; the second 
subtype covers patients with an onset of symptoms 
between birth and adolescence, but without 
persistent and/or progressive cardiac hypertrophy, 
and the third subtype covers patients with an 
onset of symptoms between adolescence and late 
adulthood.3,4
Early diagnosis and enzyme-replacement 
therapy can benefit infants with Pompe disease.5 To 
establish a diagnosis of Pompe disease, both clinical 
evaluation and diagnostic tests are required.1 
Rapid blood-based activity tests were developed 
for pre-symptomatic diagnoses at birth and for 
at-risk individuals, to allow optimal conditions for 
enzyme replacement therapy;6 however, a second 
confirmatory test is recommended to support the 
diagnoses. DNA-based testing is an approach that 
can rapidly confirm the diagnosis and identify the 
nature of the mutations (genotypes) that alter the 
level of residual enzyme activity and are responsible 
for the clinical phenotype heterogeneity.7,8
The GAA gene is about 28 Kilo-base pairs 
(Kb) long, contains 20 exons and maps to human 
chromosome 17q25.2–q25.3. The first exon is 
non-coding and the complementary DNA (cDNA) 
encodes a protein of 952 amino acids.2 Nearly 250 
mutations have been identified as causing Pompe 
disease, and they are rated by severity and divided 
into different classes.9 Some of these mutations are 
common in certain populations.2
The identification of mutations in a population 
overcomes the problem of a lengthy, time-
consuming and expensive search for a mutation 
approach—due to the size of the gene—by providing 
a limited number of mutations to be tested. This in 
turn facilitates diagnoses and aids in the counselling 
of patients and families with the disease. In this 
study, we utilised archived formalin-fixed paraffin 
embedded (FFPE) tissues in pathology laboratories 
to identify retrospectively GAA mutations causing 
Pompe disease (glycogen storage disease type 
II) in Oman, which enabled the design of a rapid 
molecular test for families with the identified 
mutations.
Methods
Archived muscle tissues were collected in 2000 and 
2002 from two infants of Arab origin (a 3-month-
old male and a 4-month-old female, respectively) 
with clinical presentations consistent with infantile 
onset Pompe disease. Both infants had presented 
with bronchitis, hypotonia and hypertrophic 
cardiomyopathy. Their creatine kinase (CK) levels 
were high at 571 u/L and 410 u/L, respectively (range 
0–6 u/L), and lactate dehydrogenase (LDH) levels 
were high at 2,415 u/L and 626 u/L, respectively 
(range 91–180 u/L). The electromyograms (EMG) 
showed mixed myopathic and neuropathic pictures. 
For the DNA extraction, 10 sections of 7 
micrometres (μm) were collected from archived 
muscle biopsies for each infant and kept in 2 ml 
microcentrifuge tubes. Normal archived muscle 
tissue sections were used as a control. DNA 
extraction was performed using a modified phenol-
chloroform extraction method.10 The sections were 
deparaffinised twice in 1 ml of pre-heated xylene 
(for 5 mins each) and then re-hydrated with 1 ml of 
99% ethanol and 95% ethanol (twice, for 3 mins). For 
digestion, the tissues were incubated overnight at 
60 ºC with 300 µl of lysis buffer solution containing 
100 µl of 5 mg/ml proteinase K (the proteinase K 
was inactivated at 95 ºC for 15 mins). To purify the 
DNA, the samples were extracted twice with 300 
µl of phenol and once with 350 µl of chloroform-
isoamyl alcohol (at a ratio of 24:1). Finally, the DNA 
was precipitated with one ml of 100% ethanol and 
one U/L of glycogen (20 mg/ml). The mix was 
incubated at -20 ºC for one hr and then centrifuged 
at 4 ºC for 15 mins at 13,000 rpm. After washing 
the pellet with 1 ml of 70% ethanol, the extracted 
DNA was left to air-dry and was then resuspended 
in 50 µl of double-distilled water (ddH2O). The 
integrity of the DNA was checked using 1% agarose 
gel electrophoresis and the quality of the DNA was 
analysed by polymerase chain reaction (PCR) for 
different primer sets that amplify different fragment 
sizes (250–500 bp). 
For the PCR and sequencing process, 17 sets 
of intronic primers flanking exons were designed 
to amplify the coding regions [Table 1]. Exon 2 is 
a large exon and was therefore amplified with two 
overlapping fragments. The primers were designed 
to amplify short fragments (193–454 bp) suitable for 
degraded DNA.11 PCR was performed using a 25 µl 
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reaction volume containing the PCR buffer, 5 µl of 
genomic DNA, 1.5 millimolars (mM) of magnesium 
chloride (MgCl2), 0.5 unified atomic mass units (U) 
of Taq DNA polymerase (Promega Corporation, 
Madison, Wisconsin, USA), 200 micromolars (µM) 
of deoxyribonucleotide triphosphates (dNTP) and 
0.5 µM of each primer.
The PCR was performed under the following 
conditions: 95 °C for 5 mins followed by 35 cycles of 
denaturation at 95 °C for 30 secs, annealing at 58–
63 °C for 30 secs and then extension at 72 °C for 30 
secs. A final extension step was carried out at 72 °C 
for 5 mins. The DNA isolated from the peripheral 
blood was used as positive controls and ddH2O was 
used as a negative control. The product was checked 
for specificity and yield using 2% agarose gel stained 
with ethidium bromide.
The direct sequencing (DS) of the PCR 
products was performed by a commercial company 
(Macrogen, Inc., Seoul, Korea). Chromatograms 
were edited and analysed using the software 
BioEdit, Version 6.0.7 (Ibis Biosciences, Carlsbad, 
California, USA). 
Regarding the restriction fragment 
polymorphism (RFLP), the mutation at codon 854 
in exon 18, c.2560C>T, correlated with a Bsu36I 
restriction site in the T allele. For the restriction 
fragment length polymorphism (RFLP) reaction, 
7 µl of the exon 18 PCR product was digested for 
4 hrs with 10 U of the Bsu36I gene (New England 
BioLabs, (UK) Ltd., Hitchin, Herts, UK ) at 37 °C. 
After the inactivation of the enzyme at 80 °C for 30 
mins, the restriction fragments were separated by 
electrophoresis using a 2.5% agarose gel. The 250 
bp PCR product was cleaved into two fragments of 
151 and 99 bp in the T allele and uncleaved in the 
C allele.  
The intron 8 splicing site mutation, c.1327-
2A>G, correlated with a SmaI restriction site in the 
G allele. For the RFLP reaction, 7 µl of exon 7 and 
8 of the PCR product was digested for 4 hrs with 
10 U of the SmaI (New England BioLabs) at 37 °C. 
After the inactivation of the enzyme at 80 °C for 30 
mins, the restriction fragments were separated by 
electrophoresis using a 2.5% agarose gel. The 252 bp 
PCR product was cleaved into two fragments of 162 
and 90 bp in the G allele and uncleaved in the A 
allele.  
The project was approved by the Ethics Research 
Committee of the College of Medicine & Health 
Sciences at Sultan Qaboos University in Muscat, 
Oman.
Results 
The examination of the muscle biopsies by light 
microscopy and electron microscopy for both 
patients showed vacuolar myopathy with storage of 
glycogen consistent with Pompe disease [Figures 1 
and 2].









2 A F ctgagcccgctttcttctc 365 61 
2 A R cactgttcctgggtgatgg 365 61
2 B F ccatcacccaggaacagtg 330 61
2 B R gtgaggtgcgtgggtgtc 330 61
3 F ggtggctgtggggaacat 210 59
3 R ctggcacagagcccagaa 210 59
4 + 5 F ggtgctctcaggctcgtgt 454 59
4 + 5 R aggcagcacggaggagac 454 59
6 F tgaagaatctgtcccccaac 342 61
6 R ggtcatgttctccaccacct 342 61
7 + 8 F ctcatgaagtcggcgttgg 400 61.5
7 + 8 R ccttcccaaagacccacagt 400 61.5
9 F cccagcctcatcctctcact 252 63
9R gctggaggcctctgctttct 252 63
10 + 11 F cactgcagcctctcgttgtc 396 58
10 + 11 R gctaagtctcccaggccaga 396 58
12 F gaggaagctccctggaaacc 202 59
12 R acaggctgtgagggcagag 202 59
13 F ctctgcctcatcccagaaag 287 63
13 R cccggctctactctgctg 287 63
14 F cctgaggaccagcctgact 248 59
14 R attcccaggggagagtcttg 248 59
15 F agcacccaagtgcttcctt 209 61.5
15 R  gcccctgcctaggtcact 209 61.5
16 F gtatgcctgtgtgcccatc 193 59
16 R ggcttagggtccccagact 193 59
17 F cccagaatcctcaaagcaac 232 61.5
17 R ctctgcagtgtgctgtccac 232 61.5
18 F cacgtgtccttccctttcc 250 61.5
18 R ccctcaccccttctcaacc 250 61.5
19 F ctgtctgctgacacctccac 239 61.5
19 R cgatccctgtgccactct 239 61.5
20 F tgctccatttgtgctctctc 200 61.5
20 R ctccaggtgacacatgcaac 200 61.5
bp = base pairs; temp. = temperature.
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DNA was successfully extracted from the two 
archived tissues from the patients with Pompe 
disease using a modified phenol-chloroform 
extraction method. The checking of the integrity and 
quality of the DNA by agarose gel electrophoresis 
and PCR, respectively, indicated a good DNA quality 
for PCR and post-PCR methods. Two mutations 
were identified in the Pompe disease samples. 
Infant 1 (female) was homozygous for mutation 
c.2560C>T (p.Arg854X) [Figure 3] and infant 2 
(male) was homozygous for mutation c.1327-2A>G 
[Figure 4]. Neither of the two identified mutations 
were found in the DNA control sample, nor was the 
sequence retrieved from the GenBank sequence 
database (NW_926918),12 but both were found in 
the Pompe Center database.13
The PCR and RFLP tests for both mutations 
were designed to be used as fast confirmatory tests 
 
Figure 1 A to F. Micrographs of infant 1. A & B: Light micrographs showing vacuolated fibres (arrows) stained with 
haematoxylin and eosin and Masson’s trichrome. C: Light micrograph showing the rich glycogen accumulation (arrows) 
with Periodic acid-Schiff (PAS) stain. D: Light micrograph showing the digested glycogen with a diastase (arrow) stained 
with PAS diastase. E: Light micrograph showing type I (arrows) and type II (arrows) fibres stained with adenosine 
triphosphatase (pH = 9.5). F: Electron micrograph showing lysosomal vacuoles containing small aggregates of glycogen 
(arrows). 
Scale is 200 µm for A–E and 500 nm for F.
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for diagnosis and screening. Typical genotyping 
results are shown in Figures 5 and 6.
Discussion
Muscle biopsies have always been considered the 
standard method for diagnosing Pompe disease.4 
However, biopsies are invasive methods requiring 
anaesthesia, which is not recommended for infants 
with Pompe disease. In 2006, enzyme replacement 
therapy became available and, to ensure the 
patient’s optimal benefit, new rapid and less invasive 
diagnostic tests were developed.4 Testing GAA in 
dried blood is one of the methods developed and it 
is considered to be reliable and suitable for newborn 
screening, as it only requires a drop of blood to 
be collected, either from the heel or using the 
finger stick method.6 However, the Pompe disease 
 
Figure 2 A to F. Micrographs of infant 2. A & B: Light micrographs showing the funicular architecture of the tissue; 
there are many vacuoles of variable sizes within the fibres (arrows) stained with haematoxylin and eosin and Masson’s 
trichrome. C: Light micrograph showing the glycogen accumulation (arrows) with Periodic acid-Schiff (PAS) stain. D: 
Light micrograph showing the digested glycogen with a diastase (arrows) stained with PAS diastase. E: Light micrograph 
showing type I and II fibres (arrows) stained with nicotinamide adenine dinucleotide-tetrazolium reductase. F: Electron 
micrograph showing lysosomal vacuoles containing aggregated granules of glycogen (arrows).
Scale is 200 µm for A–E and 500 nm for F.
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diagnostic working group emphasised the need for 
a second confirmatory test to support the clinical 
and/or biochemical diagnosis due to the absence of 
developed quality assurance measures.4
The detection of Pompe disease-causing 
mutation(s) is considered a definitive and rapid 
confirmatory test. It can be utilised in screening 
at-risk infants and for the identification of carriers, 
as well as in prenatal diagnosis and the genetic 
counselling of families with a history of Pompe 
disease.
In this retrospective study, the pathology 
archival formalin-fixed paraffin-embedded (FFPE) 
tissues provided a source of good quality DNA to 
investigate the molecular bases of Pompe disease in 
two Omani infants. 
Optimisation of the DNA extraction method 
was very important and the primers for PCR were 
designed to amplify short fragments (less than 450 
bp). The analysis of exons 2–20 of the GAA gene 
using direct sequencing identified two mutations. 
In infant 1, a c.2560C>T (p.Arg854X) mutation in a 
CpG dinucleotide, which is susceptible to recurrent 
mutations, was identified. It is a transition, nonsense 
mutation at the C-terminal end that is known to 
be associated with infantile onset Pompe disease.8 
Although found among Pakistani, Mexican-
American and French ethnicities, the mutation has 
been observed in up to 60% of patients of African 
descent with a common haplotype.2
 In infant 2, a c.1327-2A>G mutation modifying 
the splice acceptor site of exon 9 was identified. 
This mutation is associated with very severe effects, 
and has been reported in Pompe disease cases from 
UK, Iran and in patients of Arab origin.14
The presence of both mutations as a homozygous 
genotype is an indicator of parental consanguinity, 
which has been reported in more Omani patients 
with inborn errors of metabolism (81%) compared 
to the general population (33%).15 Furthermore, 
consanguineous marriage in Oman (52%) has been 
found to be dominated by first-cousin marriages 
(75%).16
Conclusion
This study provided valuable information regarding 
Pompe disease-causing mutations in the GAA 
gene and has enabled the development of specific 
molecular tests for Omani families. An RFLP test 
was developed to identify each mutation. The 
timescale for carrying out the PCR and RFLP test 
on a routine basis is about 3–8 hrs and is therefore 
fast compared to other available methods.
To the best of our knowledge, this is the first 
retrospective study to utilise FFPE tissues in Oman 
to identify the mutations causing Pompe disease. 
We were successful in identifying two Pompe 
disease-causing mutations and developing a rapid 
specific genetic test that can be used for prenatal 
 
Figure 3 Panels A & B. The c.2560C>T (p.Arg854X) 
mutation in exon 18. A: The alignment of the wild 
type and mutant sequences. B: Direct sequencing 
chromatograms for the homozygous wild type (Cont.) 
and mutation (infant 1) sequences. 
 
Figure 4 Panels A & B. The c.1327-2A>G mutation in 
intron 8. A: The alignment of the wild type and mutant 
sequences. B: Direct sequencing chromatograms 
for the homozygous wild type (Cont.) and mutation 
(infant 2) sequences. 
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diagnosis and carrier screening in Omani families 
with the identified mutations. 
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Figure 5 Panels A & B. The assay design (A) and results (B) 
of the polymerase chain reaction restriction fragment length 
polymorphism analysis for the c.2560C>T (p.Arg854X) 
mutation in exon 18. A: First, a 250 bp fragment of the GAA 
gene covering the mutation was amplified by polymerase 
chain reaction (PCR); next, the PCR product was digested 
with the Bsu36I restriction enzyme, which recognizes only 
the T allele, and generated two fragments, 151 bp and 99 bp. 
B: The electrophoretic separation of the Bsu36I enzymatic 
restriction products using 2.5% (weight/volume percentage) 
agarose gel. Lanes: 1 = DNA ladder; 2 = TT homozygote 
(mutant type) digested product; 3 = CC homozygote (wild 
type) undigested fragment (250 bp), and 4 = CC homozygote 
(wild type) undigested fragment (250 bp).  
 
Figure 6 Panels A & B. The assay design (A) and results 
(B) of the polymerase chain reaction restriction fragment 
length polymorphism analysis for the c.1327-2A>G mutation 
in intron 8. A: First, a 252 bp fragment of the GAA gene 
covering the mutation was amplified by polymerase chain 
reaction (PCR); next, the PCR product was digested with 
the SmaI restriction enzyme which recognizes only the G 
allele, and generated two fragments, 162 bp and 90 bp. B: The 
electrophoretic separation of the SmaI enzymatic restriction 
products using 2.5% (weight/volume percentage) agarose gel. 
Lanes: 1 = DNA ladder; 2 = GG homozygote (mutant type) 
digested product; 3 = GG homozygote (mutant type) digested 
product, and 4 = AA  homozygote (wild type) undigested 
fragment (252 bp).    
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